Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

20.13 -0.04 (-0.20%)
Streaming Delayed Price Updated: 1:21 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis ↗
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
News headline image
Why Is Monte Rosa Therapeutics Stock Surging On Monday? ↗
Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Leadership Team Promotions
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023 ↗
GLUE stock results show that Monte Rosa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.